Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 591 entries
View as:

Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00528398 Org: User:
Start: 09/30/94 End: 12/31/15 Due: 12/31/16

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT05757310 Org: User:
Start: 11/15/24 End: 06/18/27 Due: 06/18/28

Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant

Phase: N/A Priority: Normal
NCT ID: NCT00530218 Org: User:
Start: 03/31/99 End: 02/28/10 Due: 02/28/11

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03479268 Org: User:
Start: 03/22/18 End: 06/22/25 Due: 06/22/26

Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02082470 Org: User:
Start: 04/11/14 End: 09/26/17 Due: 09/26/18

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Phase: N/A Priority: Normal
NCT ID: NCT00544115 Org: User:
Start: 10/16/01 End: 04/02/26 Due: 04/02/27

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT03117855 Org: User:
Start: 12/31/16 End: - Due: -

On the BRINK: PhotoBiomodulation (PBM) for Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell TRansplant (HSCT) - Implementing the Evidence & Discovering New Knowledge

Phase: N/A Priority: Normal
NCT ID: NCT06625619 Org: User:
Start: 10/07/24 End: 12/05/25 Due: 12/05/26

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT01172964 Org: User:
Start: 08/31/10 End: 02/11/15 Due: 02/11/16

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05627635 Org: User:
Start: 05/03/23 End: 10/07/25 Due: 10/07/26

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02827877 Org: User:
Start: 07/15/16 End: 06/01/25 Due: 06/01/26

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02336087 Org: User:
Start: 01/14/16 End: 01/09/26 Due: 01/09/27

Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00005078 Org: User:
Start: 03/31/00 End: 07/31/12 Due: 07/31/13

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01885689 Org: User:
Start: 02/10/14 End: 10/08/25 Due: 10/08/26

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03113487 Org: User:
Start: 02/01/18 End: 06/03/25 Due: 06/03/26

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04605731 Org: User:
Start: 08/03/21 End: 08/25/25 Due: 08/25/26

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT02396134 Org: User:
Start: 05/21/15 End: 09/19/24 Due: 09/19/25

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06447987 Org: User:
Start: 11/06/24 End: 12/05/26 Due: 12/05/27

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03591744 Org: User:
Start: 10/25/18 End: 10/25/19 Due: 10/25/20

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05840770 Org: User:
Start: 04/15/25 End: 10/30/29 Due: 10/30/30

Assessment of Older Adults With Cancer: Feasibility of Computer Survey Methodology

Phase: N/A Priority: Normal
NCT ID: NCT00977834 Org: User:
Start: 07/31/09 End: 07/31/11 Due: 07/31/12

Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01205022 Org: User:
Start: 04/30/11 End: 01/31/14 Due: 01/31/15

Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)

Phase: N/A Priority: Normal
NCT ID: NCT01176253 Org: User:
Start: 07/31/09 End: 04/30/15 Due: 04/30/16

Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial

Phase: N/A Priority: Normal
NCT ID: NCT05205512 Org: User:
Start: 09/14/22 End: 06/29/25 Due: 06/29/26

Phase II Trial of Lung Chemoemobolization

Phase: N/A Priority: Normal
NCT ID: NCT05672108 Org: User:
Start: 05/12/23 End: 10/28/26 Due: 10/28/27